=>
Uploading C:\Program Files\Stnexp\Queries\10800241.str



chain nodes :
7 37 40 41 78
ring nodes :
1 2 3 4 5 6 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
25 26 27 28 29 30 31 42 43 44 45 46 47 48 49 50 51 52 53 54 55
56 57 58 59 68 69 70 71 72 73
chain bonds :
7-37 7-78 40-41 40-78
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 8-9 8-13 9-10 10-11 11-12 12-13 14-15 14-19
15-16 16-17 17-18 18-19 20-21 20-25 21-22 22-23 23-24 24-25 26-27 26-31
27-28 28-29 29-30 30-31 42-43 42-47 43-44 44-45 45-46 46-47 48-49 48-53
49-50 50-51 51-52 52-53 54-55 54-59 55-56 56-57 57-58 58-59 68-69 68-73
69-70 70-71 71-72 72-73
exact/norm bonds :

```
7-37  7-78  40-41  40-78
normalized bonds :
1-2  1-6  2-3  3-4  4-5  5-6  8-9  8-13  9-10  10-11  11-12  12-13  14-15  14-19
15-16  16-17  17-18  18-19  20-21  20-25  21-22  22-23  23-24  24-25  26-27  26-31
27-28  28-29  29-30  30-31  42-43  42-47  43-44  44-45  45-46  46-47  48-49  48-53
49-50  50-51  51-52  52-53  54-55  54-59  55-56  56-57  57-58  58-59  68-69  68-73
69-70  70-71  71-72  72-73
isolated ring systems :
containing 1 : 8 : 14 : 20 : 26 : 42 : 48 : 54 : 68 :


G1:[*1],[*2],[*3],[*4]

G2:CH2,NH

G3:[*5-*6],[*7-*8],[*9-*10],[*11-*12],[*13-*14]

Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:CLASS  8:Atom  9:Atom  10:Atom
11:Atom  12:Atom  13:Atom  14:Atom  15:Atom  16:Atom  17:Atom  18:Atom  19:Atom
20:Atom  21:Atom  22:Atom  23:Atom  24:Atom  25:Atom  26:Atom  27:Atom  28:Atom
29:Atom  30:Atom  31:Atom  37:CLASS  40:CLASS  41:Atom  42:Atom  43:Atom  44:Atom
45:Atom  46:Atom  47:Atom  48:Atom  49:Atom  50:Atom  51:Atom  52:Atom  53:Atom
54:Atom  55:Atom  56:Atom  57:Atom  58:Atom  59:Atom  68:Atom  69:Atom  70:Atom
71:Atom  72:Atom  73:Atom  78:CLASS



L1      STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1              STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY -  AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.


=> s l1 sss sam
SAMPLE SEARCH INITIATED 19:11:49 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -      353 TO ITERATE

100.0% PROCESSED      353 ITERATIONS                                  2 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:          5933 TO     8187
PROJECTED ANSWERS:                2 TO      124

L2            2 SEA SSS SAM L1

=> => s l1 sss ful
FULL SEARCH INITIATED 19:12:35 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -     6981 TO ITERATE
```

100.0% PROCESSED 6981 ITERATIONS 45 ANSWERS
SEARCH TIME: 00.00.01

L3 45 SEA SSS FUL L1

=> => s l3
L4 5 L3

=> d l4 1-5 bib,ab,hitstr

L4 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:999678 CAPLUS
DN 141:424209
TI Preparation of pyrimidine derivatives as corticotropin releasing factor inhibitors
IN Hartz, Richard A.; Arvanitis, Argyrios G.
PA USA
SO U.S. Pat. Appl. Publ., 26 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2004229891	A1	20041118	US 2004-800241	20040312
PRAI US 2003-464063P	P	20030418		

OS MARPAT 141:424209
AB The title heterocyclic antagonists I [B = CH, N; D = CH2, NH; R1 = H, CN, alkyl, etc.; R2, R3 = H, halo, CN, etc.; Ar = Ph, indanyl, pyridyl, etc.], useful for the treatment of depression, anxiety, affective disorders, feeding disorders, post-traumatic stress disorder, headache, drug addiction, inflammatory disorders, drug or alc. withdrawal symptoms and other conditions the treatment of which can be effected by the antagonism of the CRF-1 receptor, were prepared E.g., a 6-step synthesis of II, starting from 4-methoxybenzenethiol, was given. The compds. I demonstrated a Ki of less than about 10,000 nM for the inhibition of CRF in the CRF-R1 receptor binding assay. The pharmaceutical compns. comprising the title antagonists of the corticotropin releasing factor receptor ("CRF receptor") 1 are disclosed.
IT **796048-45-8P 796048-46-9P 796048-57-2P**
796048-59-4P 796048-66-3P 796048-73-2P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of pyrimidinyl Ph sulfones as corticotropin releasing factor inhibitors)
RN 796048-45-8 CAPLUS
CN 4-Pyrimidinamine, 5-[(4-methoxyphenyl)sulfonyl]-2-methyl-N-(2,4,6-trimethylphenyl)- (9CI) (CA INDEX NAME)



RN 796048-46-9 CAPLUS
CN Phenol, 4-[[2-methyl-4-[(2,4,6-trimethylphenyl)amino]-5-

pyrimidinyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 796048-57-2 CAPLUS
CN Pyrimidine, 5-[(4-methoxyphenyl)sulfonyl]-2-methyl-4-[(2,4,6-trimethylphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 796048-59-4 CAPLUS
CN 4-Pyrimidinamine, 5-[(4-fluorophenyl)sulfonyl]-2-methyl-N-(2,4,6-trimethylphenyl)- (9CI) (CA INDEX NAME)



RN 796048-66-3 CAPLUS
CN Benzonitrile, 4-[[2-methyl-4-[(2,4,6-trimethylphenyl)amino]-5-pyrimidinyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 796048-73-2 CAPLUS
CN 4-Pyrimidinamine, 5-[[4-(4,5-dihydro-1H-imidazol-2-yl)phenyl]sulfonyl]-2-methyl-N-(2,4,6-trimethylphenyl)- (9CI) (CA INDEX NAME)



IT **796048-47-0P 796048-48-1P 796048-49-2P**
796048-50-5P 796048-51-6P 796048-52-7P
796048-53-8P 796048-54-9P 796048-55-0P
796048-56-1P 796048-58-3P 796048-60-7P
796048-61-8P 796048-62-9P 796048-63-0P
796048-64-1P 796048-65-2P 796048-67-4P
796048-68-5P 796048-69-6P 796048-70-9P
796048-71-0P 796048-72-1P 796048-74-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrimidinyl Ph sulfones as corticotropin releasing factor inhibitors)

RN 796048-47-0 CAPLUS
CN Phenol, 4-[[2-methyl-4-[(2,4,6-trimethylphenyl)amino]-5-pyrimidinyl]sulfonyl]-, acetate (ester) (9CI) (CA INDEX NAME)



RN 796048-48-1 CAPLUS
CN 4-Pyrimidinamine, 2-methyl-5-[[4-(phenylmethoxy)phenyl]sulfonyl]-N-(2,4,6-trimethylphenyl)- (9CI) (CA INDEX NAME)



RN 796048-49-2 CAPLUS
CN 4-Pyrimidinamine, N-(4-methoxy-2-methylphenyl)-2-methyl-5-[[4-(phenylmethoxy)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 796048-50-5 CAPLUS
CN 4-Pyrimidinamine, N-(6-methoxy-2-methyl-3-pyridinyl)-2-methyl-5-[[4-(phenylmethoxy)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 796048-51-6 CAPLUS
CN 4-Pyrimidinamine, 2-methyl-5-[[3-(phenylmethoxy)phenyl]sulfonyl]-N-(2,4,6-trimethylphenyl)- (9CI) (CA INDEX NAME)



RN 796048-52-7 CAPLUS
CN 4-Pyrimidinamine, 2-methoxy-5-[[3-(phenylmethoxy)phenyl]sulfonyl]-N-(2,4,6-trimethylphenyl)- (9CI) (CA INDEX NAME)



RN 796048-53-8 CAPLUS
CN 2,4-Pyrimidinediamine, N2,N2-dimethyl-5-[[3-(phenylmethoxy)phenyl]sulfonyl

]-N4-(2,4,6-trimethylphenyl)- (9CI) (CA INDEX NAME)



RN 796048-54-9 CAPLUS
CN 4-Pyrimidinamine, 5-[[4-[(2-methoxyphenyl)methoxy]phenyl]sulfonyl]-2-methyl-N-(2,4,6-trimethylphenyl)- (9CI) (CA INDEX NAME)



RN 796048-55-0 CAPLUS
CN 4-Pyrimidinamine, 5-[[4-[(3,5-dimethoxyphenyl)methoxy]phenyl]sulfonyl]-2-methyl-N-(2,4,6-trimethylphenyl)- (9CI) (CA INDEX NAME)



RN 796048-56-1 CAPLUS
CN 4-Pyrimidinamine, N-(2,4-dimethoxyphenyl)-2-methyl-5-[[4-(phenylmethoxy)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 796048-58-3 CAPLUS
CN Pyrimidine, 2-methyl-5-[[4-(phenylmethoxy)phenyl]sulfonyl]-4-[(2,4,6-trimethylphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 796048-60-7 CAPLUS
CN 4-Pyrimidinamine, 2-methyl-5-[[4-(4-morpholinyl)phenyl]sulfonyl]-N-(2,4,6-trimethylphenyl)- (9CI) (CA INDEX NAME)



RN 796048-61-8 CAPLUS
CN 4-Pyrimidinamine, 2-methyl-5-[[4-(4-methyl-1-piperazinyl)phenyl]sulfonyl]-N-(2,4,6-trimethylphenyl)- (9CI) (CA INDEX NAME)



RN 796048-62-9 CAPLUS
CN 4-Pyrimidinamine, 5-[[4-(1H-imidazol-1-yl)phenyl]sulfonyl]-2-methyl-N-(2,4,6-trimethylphenyl)- (9CI) (CA INDEX NAME)



RN 796048-63-0 CAPLUS
CN 4-Pyrimidinamine, 2-methyl-5-[[4-(1-pyrrolidinyl)phenyl]sulfonyl]-N-(2,4,6-trimethylphenyl)- (9CI) (CA INDEX NAME)



RN 796048-64-1 CAPLUS
CN 4-Pyrimidinamine, 2-methyl-5-[[4-[(phenylmethyl)amino]phenyl]sulfonyl]-N-(2,4,6-trimethylphenyl)- (9CI) (CA INDEX NAME)



RN 796048-65-2 CAPLUS
CN 4-Pyrimidinamine, 2-methyl-5-[[4-[methyl(phenylmethyl)amino]phenyl]sulfonyl]-N-(2,4,6-trimethylphenyl)- (9CI) (CA INDEX NAME)



RN 796048-67-4 CAPLUS
CN 4-Pyrimidinamine, 2-methyl-5-[(4-methylphenyl)sulfonyl]-N-(2,4,6-trimethylphenyl)- (9CI) (CA INDEX NAME)



RN 796048-68-5 CAPLUS
CN 4-Pyrimidinamine, 2-methyl-5-[[4-(5-pyrimidinyl)phenyl]sulfonyl]-N-(2,4,6-trimethylphenyl)- (9CI) (CA INDEX NAME)



RN 796048-69-6 CAPLUS

CN 4-Pyrimidinamine, 2-methyl-5-[[4-(2-pyrimidinyl)phenyl]sulfonyl]-N-(2,4,6-trimethylphenyl)- (9CI) (CA INDEX NAME)



RN 796048-70-9 CAPLUS
CN 4-Pyrimidinamine, 2-methyl-5-[[4-(4-pyridinyl)phenyl]sulfonyl]-N-(2,4,6-trimethylphenyl)- (9CI) (CA INDEX NAME)



RN 796048-71-0 CAPLUS
CN 4-Pyrimidinamine, 2-methyl-5-[[4-(2-pyridinyl)phenyl]sulfonyl]-N-(2,4,6-trimethylphenyl)- (9CI) (CA INDEX NAME)



RN 796048-72-1 CAPLUS
CN 4-Pyrimidinamine, 2-methyl-5-[[4-(3-pyridinyl)phenyl]sulfonyl]-N-(2,4,6-trimethylphenyl)- (9CI) (CA INDEX NAME)



RN 796048-74-3 CAPLUS
CN 4-Pyrimidinamine, 5-[[4-(1H-imidazol-2-yl)phenyl]sulfonyl]-2-methyl-N-(2,4,6-trimethylphenyl)- (9CI) (CA INDEX NAME)



IT **796048-81-2P**, Trifluoromethanesulfonic acid 4-[2-methyl-4-(2,4,6-trimethylphenylamino)-pyrimidin-5-ylsulfonyl]phenyl ester
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyrimidinyl Ph sulfones as corticotropin releasing factor inhibitors)
RN 796048-81-2 CAPLUS
CN Methanesulfonic acid, trifluoro-, 4-[[2-methyl-4-[(2,4,6-trimethylphenyl)amino]-5-pyrimidinyl]sulfonyl]phenyl ester (9CI) (CA INDEX NAME)


O
O
S
CF3
O
O
S
O
Me
Me
NH
N
N
Me
Me

L4 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2001:650995 CAPLUS
DN 136:70036
TI Synthesis and biological evaluation of clitocine analogues as adenosine kinase inhibitors
AU Lee, Chih-Hung; Daanen, Jerome F.; Jiang, Meiqun; Yu, Haixia; Kohlhaas, Kathy L.; Alexander, Karen; Jarvis, Michael F.; Kowaluk, Elizabeth L.; Bhagwat, Shripad S.
CS Neurological and Urological Diseases Research, Global Pharmaceutical Products Division, Abbott Laboratories, Abbott Park, IL, 60064, USA
SO Bioorganic & Medicinal Chemistry Letters (2001), 11(18), 2419-2422
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier Science Ltd.
DT Journal
LA English
OS CASREACT 136:70036
AB Adenosine kinase (AK) is the primary enzyme responsible for adenosine metabolism Inhibition of AK effectively increases extracellular adenosine concns. and represents an alternative approach to enhance the beneficial actions of adenosine as compared to direct-acting receptor agonists. Clitocine, isolated from the mushroom Clitocybe inversa, has been found to be a weak inhibitor of AK. We have prepared a number of analogs of clitocine in order to improve its potency and demonstrated that 5'-deoxy-5'-amino-clitocine (I) improved AK inhibitory potency by 50-fold.
IT **385370-22-9P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of clitocine analogs for use as adenosine kinase inhibitors)
RN 385370-22-9 CAPLUS
CN β-D-Ribofuranosylamine, N-[6-amino-5-(phenylsulfonyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2000:508630 CAPLUS
DN 133:281746
TI Novel inhibitors of AP-1 and NF-κB mediated gene expression: structure-activity relationship studies of ethyl 4-[(3-Methyl-2,5-dioxo(3-pyrrolinyl))amino]-2-(trifluoromethyl)pyrimidine-5-carboxylate
AU Palanki, M. S. S.; Erdman, P. E.; Manning, A. M.; Ow, A.; Ransone, L. J.; Spooner, C.; Suto, C.; Suto, M.
CS Signal Pharmaceuticals, Inc., San Diego, CA, 92121, USA
SO Bioorganic & Medicinal Chemistry Letters (2000), 10(15), 1645-1648
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier Science Ltd.
DT Journal
LA English
OS CASREACT 133:281746
AB In an effort to identify novel inhibitors of AP-1 and NF-κB mediated transcriptional activation, several analogs of Et 4-[(3-methyl-2,5-dioxo(3-pyrrolinyl))amino]-2-(trifluoromethyl)pyrimidine-5-carboxylate were synthesized and tested in two in vitro assays. The 2-(2'-thienyl) substituted compound was identified as the most potent in this series.
IT **299423-72-6P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation as inhibitor for AP-1 and NF-κB transcription factors)
RN 299423-72-6 CAPLUS
CN 5-Pyrimidinecarboxylic acid, 4-[(2,5-dihydro-3-methyl-2,5-dioxo-1H-pyrrol-1-yl)amino]-2-(phenylsulfonyl)-, ethyl ester (9CI) (CA INDEX NAME)



RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1990:20961 CAPLUS
DN 112:20961
TI Synthesis of some 2,4-diamino-6-substituted-amino-5-arylpyrimidines
AU Shishoo, C. J.; Devani, M. B.; Jain, K. S.; Bhadti, V. S.; Shishoo, S. M.; Pathak, U. S.; Ananthan, S.; Rathod, I. S.
CS Dep. Pharm. Chem., L. M. Coll. Pharm., Ahmedabad, 380 009, India
SO Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry (1989), 28B(1), 42-7
CODEN: IJSBDB; ISSN: 0376-4699
DT Journal
LA English
OS CASREACT 112:20961
AB Condensation reaction of α-cyanoketene S,N-acetals with guanidine gave 25 5-aryl, -arylthio and -arylsulfonyl-2,4-diamino-6-substituted-aminopyrimidines I as potential antimalarial compds. Of the 13 diaminopyrimidines tested for antimalarial activity only one compound (R = 4-ClC6H4SO2, R2 = 4-MeOC6H4) exhibits significant activity in in vitro screening tests against Indochina W-2 clone of P. falciparum. 2,4-Diaminopyrimidines I (R = 4-ClC6H4, R1 = 2-MeOC6H4; R = 4-MeC6H4S, R1 = 2-MeC6H4) have shown broad spectrum antibacterial activity.
IT **124392-48-9P 124392-50-3P 124392-51-4P**
124392-52-5P 124392-53-6P 124392-54-7P
124392-55-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and antimalarial activity of)
RN 124392-48-9 CAPLUS
CN 2,4,6-Pyrimidinetriamine, 5-[(4-chlorophenyl)sulfonyl]-N4-phenyl- (9CI) (CA INDEX NAME)



RN 124392-50-3 CAPLUS
CN 2,4,6-Pyrimidinetriamine, 5-[(4-chlorophenyl)sulfonyl]-N4-(2-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 124392-51-4 CAPLUS
CN 2,4,6-Pyrimidinetriamine, 5-[(4-chlorophenyl)sulfonyl]-N4-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 124392-52-5 CAPLUS
CN 2,4,6-Pyrimidinetriamine, 5-[(4-chlorophenyl)sulfonyl]-N4-(4-ethoxyphenyl)- (9CI) (CA INDEX NAME)



RN 124392-53-6 CAPLUS
CN 2,4,6-Pyrimidinetriamine, 5-[(4-methylphenyl)sulfonyl]-N4-phenyl- (9CI) (CA INDEX NAME)



RN 124392-54-7 CAPLUS
CN 2,4,6-Pyrimidinetriamine, N4-(2-methylphenyl)-5-[(4-methylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 124392-55-8 CAPLUS
CN 2,4,6-Pyrimidinetriamine, N4-(4-methoxyphenyl)-5-[(4-methylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)



IT **124392-49-0P 124392-56-9P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 124392-49-0 CAPLUS
CN 2,4,6-Pyrimidinetriamine, 5-[(4-chlorophenyl)sulfonyl]-N4-(2-methylphenyl)- (9CI) (CA INDEX NAME)



RN 124392-56-9 CAPLUS
CN 2,4,6-Pyrimidinetriamine, N4-(4-methylphenyl)-5-(phenylsulfonyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1981:208799 CAPLUS
DN 94:208799
TI Studies on pyrimidine derivatives. XXI. Nucleophilic substitution of 4-chloropyrimidines and related compounds with carbanions
AU Yamanaka, Hiroshi; Ogawa, Shigeru; Konno, Shoetsu
CS Pharm. Inst., Tohoku Univ., Sendai, 980, Japan
SO Chemical & Pharmaceutical Bulletin (1981), 29(1), 98-104
CODEN: CPBTAL; ISSN: 0009-2363
DT Journal
LA English
OS CASREACT 94:208799
AB The reaction of 4-chloro-2,6-dimethylpyrimidine 1-oxide (I) with Et cyanoacetate or malononitrile under basic conditions gave the expected condensation products, while the reaction of I with methylene ketones failed. On the other hand, 2,6-dimethyl-4-phenylsulfonylpyrimidine smoothly reacted not only with the above active Me compds. but also with methylene ketones such as acetone, acetophenone, and cyclohexanone.
IT **77752-55-7P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 77752-55-7 CAPLUS
CN Pyrimidine, 2,4-dimethyl-6-[[2-methyl-6-[(4-methylphenyl)sulfonyl]-3-oxido-4-pyrimidinyl]methyl]-, 3-oxide (9CI) (CA INDEX NAME)



```
=> => d his

     (FILE 'HOME' ENTERED AT 19:11:13 ON 01 MAR 2006)

     FILE 'REGISTRY' ENTERED AT 19:11:17 ON 01 MAR 2006
L1               STRUCTURE UPLOADED
L2             2 S L1 SSS SAM
L3            45 S L1 SSS FUL

     FILE 'CAPLUS' ENTERED AT 19:12:42 ON 01 MAR 2006
L4             5 S L3

     FILE 'CAOLD' ENTERED AT 19:13:07 ON 01 MAR 2006

=> s l3
L5             0 L3

=> log y
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.44     194.04

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                       0.00      -3.75

STN INTERNATIONAL LOGOFF AT 19:13:20 ON 01 MAR 2006
```